Arbutus Biopharma Corp (ABUS) earnings date
Mar 11, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 10% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 44 days, typically, give or take 20 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Tue, Nov 10, 2026 | before open | 41 | 8-K |
| Q2 FY2026 | Wed, Aug 12, 2026 | before open | 43 | 8-K |
| Q1 FY2026 | Wed, May 13, 2026 | before open | 43 | 8-K |
| Q4 FY2025 | Mon, Mar 23, 2026 | before open | 82 | 8-K |
| Q3 FY2025 | Thu, Nov 13, 2025 | before open | 44 | 8-K |
| Q2 FY2025 | Wed, Aug 6, 2025 | before open | 37 | 8-K |
| Q1 FY2025 | Wed, May 14, 2025 | before open | 44 | 8-K |
| Q4 FY2024 | Thu, Mar 27, 2025 | before open | 86 | 8-K |
What they guided beta
| Q2 FY2026 | "EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026 Received first payment of approximately $178M from Moderna settlement in July and expects to return up to approximately $230M in capital to Arbutus shareholders Filed three international patent enforcement lawsuits against Pfizer and BioNTech related to lipid nanoparticle (LNP) technology Achieved alignment with the U.S. Food a" exhibit |
| Q2 FY2026 | "In addition, the Company owns approximately 16% of the outstanding common equity of Genevant and anticipates the payment of a material dividend from Genevant in the third quarter of 2026." exhibit |
| Q2 FY2026 | "Corporate Updates Arbutus expects to return capital to shareholders commencing in Q3 2026 through repurchases of up to approximately $230 million of the Company’s common shares, which repurchases may come in the form of a tender offer (including a modified “Dutch Auction” tender offer), open market purchases, accelerated share repurchases or other means." exhibit |
| Q1 FY2026 | "Under the Company’s license with Genevant, the Company expects to receive in July 2026 an estimated $178.7 million of the Noncontingent Settlement Payment, which includes reimbursement of the Company’s litigation costs." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/ABUS
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/ABUS
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/ABUS/"><img src="https://veritasdata.dev/embed/ABUS.svg" alt="ABUS earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/ABUS/)
Script
<script async src="https://veritasdata.dev/embed/ABUS.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/ABUS"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.